查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1835464

肝纖維化治療市場（依藥物類別、作用機制、給藥途徑和通路）－全球預測 2025-2032

Liver Fibrosis Drugs Market by Drug Class, Mechanism Of Action, Route Of Administration, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年肝纖維化治療市場將成長至 337 億美元，複合年成長率為 10.12%。

主要市場統計數據
基準年2024年 155.7億美元
預計2025年 171.2億美元
預測年份：2032年 337億美元
複合年成長率（%） 10.12%

對治療、監管和商業性格局的進展以及肝纖維化藥物開發和相關人員進行權威介紹

肝纖維化是尚未滿足的臨床需求、科學創新和商業機會的關鍵交會點。過去十年，創傷治療、細胞外基質重塑和免疫代謝的進展已將纖維化進展重新定義為一個可控制的治療標靶，而非不可避免的臨床終點。這種模式轉移帶來了更多樣化的治療方法，促進了肝病學和免疫學專家之間的跨學科合作，並強化了將機制與臨床結果聯繫起來的轉化生物標記的重要性。

臨床醫生、付款人和開發者目前專注於通用的優先事項：提高診斷準確性、在疾病發展過程中更早地進行干預，以及在確保長期用藥安全性的同時，證明纖維化的持久逆轉。同時，監管機構也表現出願意接受新的終點和適應性試驗設計，前提是採用經過嚴格檢驗的替代。這些動態創造了一個複雜的環境，在這個環境中，科學前景必須與供應鏈彈性和報銷途徑等營運現實相平衡。

本報告重點關注新興療法、平台技術和相關人員獎勵如何相互作用以形成發展策略，旨在提供清晰、可操作的綜合方案，以協助必須同時應對科學複雜性、監管細微差別和商業性要求的決策者。

科學突破、擴展模式和創新試驗設計如何推動肝纖維化治療策略和相關人員行為的根本變化

在科學突破、治療模式多樣化和臨床試驗架構變革的推動下，肝纖維化的模式正在發生重大轉變。纖維化訊號網路的分子闡明使得標靶辨識更加精準，生物製藥、細胞和基因治療以及小分子藥物設計的進步也擴展了治療套件。隨著治療方法日益多樣化，研發人員擴大根據疾病表現型調整治療促進要素，優先考慮調節纖維化核心促進因素的藥物，而非僅僅廣泛抑制相關發炎。

臨床試驗設計和患者識別領域的創新也正在重塑臨床開發。非侵入性診斷和數位生物標記物正在推動更早的入組和更有效率的生物效應評估。這些工具有助於縮短概念驗證試驗的時間，提高資訊量，從而降低風險並加快「通過/不通過」的決策。同時，產學夥伴關係也變得越來越重要，將具有互補專業知識和能力的團隊結合起來，以應對複雜的轉化挑戰。

商業性來看，定價和可及性策略正隨著差異化治療方法的出現而不斷演變。付款方更重視透過真實世界證據和持續的臨床效用來證明價值，而申辦者則在研發早期就將衛生經濟學和療效研究納入其中。總而言之，這些轉變標誌著一個日趨成熟的領域，其中科學創新正日益與務實、注重療效的研發路徑相結合。

評估近期美國關稅政策的變化如何改變肝纖維化藥物開發商的供應鏈彈性、籌資策略和商業規劃

美國近期的關稅政策變化，使支持藥品開發和商業化的全球供應鏈變得更加複雜。關稅調整不僅影響了原料藥的採購，也影響了專用生技藥品生產投入的採購。依賴跨境採購的製造商必須重新評估供應商合約、庫存策略和成本結構，以保持供應的連續性並保護利潤率。

為了應對這種情況，許多公司正在多元化供應商基礎、將關鍵製造流程分包出去或擴大關鍵原料的庫存，以緩解中斷的影響。這些營運轉變也影響著外包決策和製造外包關係，促進了更緊密的合作，並提高了前置作業時間和產能限制的透明度。同時，監管團隊正在管理製造地變更對產品標籤、進口文件和品質監管的影響。

策略定價和報銷談判也受到了類似的影響，商業團隊正在重新調整其上市策略，以應對到岸成本的潛在成長。同時，整個價值鏈上的相關人員高度重視供應鏈彈性、雙重採購和情境規劃。總而言之，這些變化凸顯了整合監管、營運和商業規劃的重要性，以便在不斷變化的貿易政策中保持臨床發展勢頭並確保患者獲得藥物。

將藥物類別、作用機制、給藥途徑和分銷管道聯繫起來的多維細分洞察，為開發和商業化策略提供訊息

了解細分市場對於將研究和商業策略與治療機會相結合至關重要。治療藥物可依藥物類別分類，涵蓋生物製劑、細胞療法、基因療法和小分子抑制劑。小分子抑制劑包括天然產物衍生的骨架和合成最佳化的化合物，這些化合物可口服給藥並進入細胞內標靶。

基於機制的細分透過突出 ASK1 抑制劑、半乳糖凝集素 3 抑制劑、PPAR促效劑和 TGFBETA 阻斷劑作為不同的機制方法，進一步細化了優先順序。 PPAR 軸本身細分為 PPARα、PPARδ 和 PPARγ，每種軸都表現出不同的代謝和纖維化生物學特性，可根據患者的表現型和合併症情況進行客製化。給藥途徑對於依從性和慢性治療方案至關重要。靜脈或皮下注射療法往往支持受控藥物動力學和基於臨床的給藥模式，而口服製劑則有利於門診病人管理和更廣泛的應用。

分銷管道影響商業性執行和病患可及性。醫院藥房為急診和住院患者提供複雜的生物製藥和輸液療法；在線藥房為穩定的慢性病治療方案提供便利性和連續性；零售藥房（包括連鎖藥房和獨立藥房）則為門診配藥和直接面向患者提供便利。這些相互交織的細分視角提供了一個多維框架，用於確定開發優先順序、設計臨床方案以及製定反映藥物形態、機制、給藥途徑和分銷現狀的上市策略。

區域發展和准入動態影響全球多個醫療保健生態系統的監管參與、證據生成和商業性執行

區域動態對研發重點、監理參與度和商業性取得途徑有重大影響。在美洲，監管機構和付款方強調真實世界療效和基於價值的契約，獎勵申辦方設計能夠證明持續臨床療效並降低醫療成本的證據生成策略。全部區域的臨床網路和學術中心也為患者招募和生物標記檢驗工作做出了貢獻，形成了早期試驗設計和轉化研究合作。

在歐洲、中東和非洲，監管協調工作和多樣化的醫療保健服務模式要求採用獨特的臨床試驗實施和市場准入規劃方法。雖然歐洲的監管途徑通常優先考慮可比性和效益提升的證明，但衛生技術評估流程的地區差異意味著證據包必須根據當地付款人的期望進行量身定做。在中東和非洲部分地區，基礎設施限制和不同的使用模式影響實施研究和可近性計畫的設計。

亞太地區擁有多樣化的臨床和商業環境，包括強大的生技藥品生產能力、不斷成長的臨床試驗能力以及快速普及的數位醫療工具。各國的法規和報銷途徑要求儘早與當地相關人員溝通。綜合來看，這些區域特徵凸顯了製定適應性監管策略、兼顧文化差異的病人參與以及與該地區支付方和醫療服務提供者優先事項相一致的證據計劃的必要性。

各公司的策略、夥伴關係和平台能力如何整合，以推進肝纖維化治療的差異化產品線和協作方式

各公司在肝纖維化領域的策略特點是平台主導創新、有針對性的產品開發和策略合作相結合。生技公司正在利用靈活的轉化醫學產品線和有針對性的患者識別策略，推動差異化機制和First-in-Class藥物的研發。大型製藥公司也擴大尋求與創新者合作，以獲得規模、監管經驗和商業化基礎設施，從而加速後期開發並擴大其治療組合。

委外研發機構)和合約開發與生產組織 (CDMO) 在加快生物製藥和小分子藥物專案的研發進度和提升產能方面發揮關鍵作用。這些合作夥伴支持靈活的研究設計、複雜的供應鏈協調以及跨司法管轄區的監管申報。策略聯盟、授權協議和共同開發契約屢見不鮮，將小型研發機構的科學研究創新能力與成熟企業的商業性和監管能力結合。

縱觀競爭格局，差異化將源自於能否展現臨床療效、適合長期用藥的安全性，以及透過經過驗證的生物標記展示機制參與的能力。整合轉化科學、以患者為中心的臨床試驗設計和穩健的商業計劃的公司，將能夠更有效地應對複雜的報銷流程和相關人員的期望。我們強調合作而非正面競爭，這反映了應對纖維化疾病生物學問題的複雜性以及互補能力的價值。

實際可行的策略性舉措，將轉化生物標記、供應鏈彈性、區域監管參與和夥伴關係模式結合起來，推動治療藥物的成功上市

行業領導者應優先考慮一系列切實可行的舉措，將科學前景與營運和商業現實相結合。首先，儘早整合轉化生物標記策略，以降低臨床計畫風險，並確保作用機制與臨床終點之間的明確關聯。這種整合將有助於與監管機構的對話，並強化對付款人的價值提案。其次，投資於供應鏈的韌性，包括實現關鍵投入的供應商多元化、評估區域製造方案以及製定緊急時應對計畫，以保持臨床和商業性的連續性。

新興創新者應尋求合作夥伴進行後期開發和商業化，而現有企業則可以透過有針對性的授權合約和共同開發契約來加速創新。第四，使區域策略與當地監管環境和付款人保持一致，並與衛生技術評估組織和區域臨床網路合作，以確保證據包符合當地要求。最後，設計反映給藥途徑和分銷動態的商業模式：確保為注射療法提供適當的臨床支持，並為口服療法提供順暢的零售和線上履約。

透過實施這些建議，組織可以將科學進步轉化為持續的臨床影響，同時管理營運複雜性並獎勵相關人員，使其與開發和商業化路徑保持一致。

結合專家初步訪談、系統性的二次文獻綜述和商業分析的嚴格混合方法研究途徑將檢驗治療和商業見解

本報告背後的研究融合了多種調查方法，以確保其觀點的可靠性和實證性。主要研究包括對肝病臨床專家、監管顧問、行業高管和供應鏈專業人士的結構化訪談，以了解當前的實踐模式、監管預期和營運限制。這些定性見解被整合在一起，以理解不同治療方法的差異化，並揭示影響開發和商業化策略的決策點。

二次研究包括對同行評審文獻、臨床試驗註冊庫和公開的監管指南進行系統性回顧，以闡明機制原理、臨床終點和轉化生物標記。營運分析利用產業報告，包括生產能力、供應鏈框架和分銷模式，評估其對研發和上市的實際影響。在整個過程中，我們運用證據三角檢定來驗證結論，並確保解讀能反映多種觀點。

透過由領域專家和跨職能評審員反覆檢驗，確保分析的嚴謹性。該方法優先考慮清晰度和可重複性，並專注於將機制科學與臨床試驗設計和商業性執行相結合。這種方法支持決策者基於科學證據和可行性尋求可操作的資訊。

結論性綜合強調了在科學、臨床開發、運作和商業性執行方面可採取的優先事項，以實現肝纖維化的持續治療效益

摘要：肝纖維化治療領域正從概念走向實際應用。生物目標和模態工程的科學進步正在拓展可行的治療方法，而診斷和檢測設計的創新則使概念驗證更有效率。同時，從供應鏈轉移到與關稅相關的採購考量，研發、製造和商業團隊需要進行一體化規劃。

在這種環境下取得成功，取決於將機制理解與轉化生物標記相結合，設計以患者為中心的臨床項目，以反映給藥途徑和藥物分配的實際情況，並儘早透過強力的證據策略與付款方和監管機構進行溝通。策略聯盟和適應性營運模式將是關鍵的推動因素，使組織能夠將科學差異化與規模化和市場化專業知識相結合。

本報告始終倡導以結果為導向的方法，強調可衡量的臨床效益、持續的患者療效以及切實可行的獲取途徑。那些擁抱數據驅動型開發、優先考慮供應鏈韌性、並尋求與其內部能力互補的夥伴關係關係的相關人員，將最有能力將科學創新轉化為持續的臨床和商業性成功。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 一種針對肝纖維化患者的發炎和纖維化的新型聯合治療
  • 非侵入性成像生物標記的進展加速了肝纖維化進展的早期檢測
  • 在開發治療肝纖維化的藥物時，使用基因組和代謝生物標記的分層臨床試驗設計來選擇患者
  • 監管進展支持加速肝病治療中新型抗纖維化藥物的核准途徑
  • 生技公司與學術機構進行策略合作，共同探索下一代纖維化抑制劑
  • 在慢性肝纖維化治療方法中，口服小分子療法的應用日益增多，而非注射劑
  • 纖維化藥物的高定價策略和受報銷政策變化影響的市場進入挑戰
  • 整合數位健康解決方案，實現肝纖維化治療反應的遠端監控
  • 來自縱向疾病登記的真實世界證據塑造了臨床指南和市場滲透策略

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 肝纖維化藥物市場（依藥物類別）

  • 生物治療
    • 單株抗體
    • 重組蛋白
  • 細胞療法
  • 基因治療
  • 小分子抑制劑
    • 天然產品
    • 合成化合物

9. 肝纖維化藥物市場（依作用機轉）

  • ASK1抑制劑
  • 半乳糖凝集素-3抑制劑
  • PPAR促效劑
    • 過氧化物酶體增殖物激活受體α
    • Delta
    • 過氧化物酶體增殖物激活受體γ
  • TGF-BETA阻斷劑

第 10 章肝纖維化藥物市場（依給藥途徑）

  • 注射
    • 靜脈
    • 皮下
  • 口服

第11章肝纖維化藥物市場按分銷管道

  • 醫院藥房
  • 網路藥局
  • 零售藥局
    • 連鎖藥局
    • 獨立藥房

第12章肝纖維化藥物市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章肝纖維化藥物市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章肝纖維化藥物市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Gilead Sciences, Inc.
    • AbbVie Inc.
    • F. Hoffmann-La Roche Ltd.
    • Bristol-Myers Squibb Company
    • Pfizer Inc.
    • Novartis AG
    • Takeda Pharmaceutical Company Limited
    • Merck & Co., Inc.
    • Intercept Pharmaceuticals, Inc.
    • Madrigal Pharmaceuticals, Inc.
Product Code: MRR-437A5D08AE2D

The Liver Fibrosis Drugs Market is projected to grow by USD 33.70 billion at a CAGR of 10.12% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 15.57 billion
Estimated Year [2025] USD 17.12 billion
Forecast Year [2032] USD 33.70 billion
CAGR (%) 10.12%

An authoritative introduction to the evolving therapeutic, regulatory, and commercial context shaping liver fibrosis drug development and stakeholder priorities

Liver fibrosis occupies a pivotal intersection of unmet clinical need, scientific innovation, and commercial opportunity. Over the past decade, advances in understanding wound healing, extracellular matrix remodeling, and immunometabolism have reframed fibrotic progression as a tractable therapeutic target rather than an inexorable clinical endpoint. This paradigm shift has catalyzed more diverse therapeutic modalities, encourages cross-disciplinary collaboration between hepatology and immunology experts, and elevates the importance of translational biomarkers that link mechanism to clinical outcomes.

Clinicians, payers, and developers now converge on common priorities: improving diagnostic precision, intervening earlier in the disease course, and demonstrating durable reversal of fibrosis while ensuring safety for chronic administration. Concurrently, regulatory agencies are signaling a willingness to engage on novel endpoints and adaptive trial designs, contingent on rigorously validated surrogate measures. These dynamics create a complex environment where scientific promise must be balanced against operational realities such as supply chain resilience and reimbursement pathways.

Throughout this report, emphasis is placed on how emerging therapies, platform technologies, and stakeholder incentives interact to shape development strategies. The intent is to provide a clear, actionable synthesis that supports decision-makers who must navigate scientific complexity, regulatory nuance, and commercial imperatives simultaneously.

How scientific breakthroughs, modality expansion, and innovative trial designs are driving a fundamental transformation in liver fibrosis therapeutic strategies and stakeholder behavior

The liver fibrosis landscape is undergoing transformative shifts driven by scientific breakthroughs, modality diversification, and changes in clinical trial architecture. Molecular deconvolution of fibrogenic signaling networks has enabled more precise target identification, while advances in biologics, cell and gene therapies, and small molecule design have expanded the therapeutic toolkit. As modalities diversify, developers are increasingly matching mechanism to disease phenotype, prioritizing agents that modulate core drivers of fibrogenesis rather than broadly suppressing associated inflammation.

Clinical development is also being reshaped by innovations in trial design and patient identification. Noninvasive diagnostics and digital biomarkers are enabling earlier enrollment and more efficient assessment of biological effect. These tools facilitate shorter, more informative proof-of-concept studies that reduce risk and accelerate go/no-go decisions. At the same time, partnerships across industry, academia, and contract research organizations are growing in importance as teams combine complementary expertise and capabilities to address complex translational challenges.

Commercially, pricing and access strategies are evolving in tandem with therapeutic differentiation. Payers are focusing on value demonstration through real-world evidence and durable clinical benefit, which is prompting sponsors to incorporate health economics and outcomes research earlier in development. Taken together, these shifts indicate a maturing field where scientific innovation is increasingly paired with pragmatic, outcome-focused development pathways.

Assessing how recent United States tariff shifts have reshaped supply chain resilience, sourcing strategies, and commercial planning across liver fibrosis drug development

Recent tariff policy developments in the United States have introduced a layer of complexity to the global supply chains that underpin drug development and commercialization. Tariff adjustments affect both the procurement of active pharmaceutical ingredients and the sourcing of specialized biologics manufacturing inputs. Manufacturers that rely on cross-border component sourcing have needed to reassess supplier contracts, inventory strategies, and cost structures in order to preserve supply continuity and protect margins.

In response, many organizations have diversified their supplier base, reshored critical manufacturing steps, or expanded inventories of key raw materials to mitigate disruption. These operational shifts have also influenced outsourcing decisions and relationships with contract development and manufacturing organizations, prompting tighter collaboration and increased transparency around lead times and capacity constraints. Regulatory teams, in parallel, are managing the implications for product labeling, import documentation, and quality oversight when manufacturing footprints change.

Strategic pricing and reimbursement discussions have been affected as well, with commercial teams recalibrating launch strategies to account for potential increases in landed costs. Meanwhile, stakeholders across the value chain are placing higher priority on supply chain resilience, dual sourcing, and scenario planning. Collectively, these changes underscore the importance of integrating regulatory, operations, and commercial planning to maintain clinical momentum and ensure patient access amid evolving trade policies.

Multidimensional segmentation insights that connect drug class, mechanism of action, administration route, and distribution channels to inform development and commercialization strategy

Understanding segmentation is essential to aligning research and commercial strategies with therapeutic opportunity. When therapies are organized by drug class, the field spans biologic therapies, cell therapies, gene therapies, and small molecule inhibitors. Within the biologic category, attention centers on monoclonal antibodies and recombinant proteins as platforms that offer target specificity and modulated immune engagement, while small molecule inhibitors encompass both natural product-derived scaffolds and synthetically optimized compounds that enable oral dosing and intracellular target access.

Mechanism-based segmentation further refines prioritization by highlighting ASK1 inhibitors, galectin-3 inhibitors, PPAR agonists, and TGF beta blockers as distinct mechanistic approaches. The PPAR axis itself is subdivided into PPAR alpha, PPAR delta, and PPAR gamma, each presenting differentiated metabolic and fibrotic biology that can be matched to patient phenotypes and comorbidity profiles. Route of administration matters for adherence and chronic treatment planning; injectable therapies, administered either intravenously or subcutaneously, tend to support controlled pharmacokinetics and clinic-based dosing models, whereas oral formulations facilitate outpatient management and broader uptake.

Distribution channels influence commercial execution and patient access. Hospital pharmacies serve acute and inpatient settings where complex biologics and infusion therapies are delivered, online pharmacies enable convenience and continuity for stable chronic regimens, and retail pharmacies-comprising chain and independent outlets-drive outpatient dispensing and direct-to-patient accessibility. Together, these intersecting segmentation lenses offer a multidimensional framework to prioritize development, design clinical programs, and craft go-to-market strategies that reflect modality, mechanism, administration route, and distribution realities.

Regional development and access dynamics that shape regulatory engagement, evidence generation, and commercial execution across multiple global healthcare ecosystems

Regional dynamics exert a profound influence on development priorities, regulatory engagement, and commercial access pathways. In the Americas, regulatory agencies and payers emphasize real-world effectiveness and value-based contracting, which incentivizes sponsors to design evidence generation strategies that demonstrate durable clinical outcomes and cost-of-care impacts. Clinical networks and academic centers across the region also contribute to patient recruitment and biomarker validation efforts, shaping early-phase study design and translational research collaborations.

Across Europe, Middle East & Africa, regulatory harmonization efforts and varying healthcare delivery models require tailored approaches to clinical trial execution and market access planning. European regulatory pathways often prioritize comparability and demonstration of incremental benefit, while regional variations in health technology assessment processes mean that evidence packages must be calibrated to local payer expectations. In parts of the Middle East and Africa, constrained infrastructure and differing prevalence patterns influence the design of implementation studies and access programs.

The Asia-Pacific region presents diverse clinical and commercial environments, with strong capabilities in biologics manufacturing, growing clinical trial capacity, and rapid adoption of digital health tools. Country-specific regulations and reimbursement pathways necessitate early engagement with local stakeholders. Taken together, these regional contours underscore the need for adaptive regulatory strategies, culturally informed patient engagement, and evidence plans that align with payer and provider priorities across geographies.

How company strategies, partnerships, and platform capabilities are converging to drive differentiated pipelines and collaborative approaches in liver fibrosis therapeutics

Company strategies in liver fibrosis are characterized by a mix of platform-driven innovation, targeted product development, and strategic collaboration. Biotech firms are advancing differentiated mechanisms and first-in-class assets, leveraging nimble translational pipelines and focused patient-identification strategies. Larger pharmaceutical companies contribute scale, regulatory experience, and commercialization infrastructure, and increasingly seek partnerships with innovators to accelerate late-stage development and broaden therapeutic portfolios.

Contract research organizations and contract development and manufacturing organizations play a critical role in accelerating timelines and enabling flexible capacity for both biologics and small molecule programs. These partners support adaptive trial designs, complex supply chain coordination, and regulatory submissions across multiple jurisdictions. Strategic alliances, licensing agreements, and co-development deals are common as organizations combine strengths: scientific ingenuity from smaller developers paired with commercial and regulatory capabilities from established firms.

Across the competitive landscape, differentiation arises from clinical efficacy signals, safety profiles amenable to chronic administration, and the ability to demonstrate mechanistic engagement through validated biomarkers. Companies that integrate translational science, patient-centric trial designs, and robust commercial planning are positioned to navigate reimbursement complexities and stakeholder expectations more effectively. The emphasis on collaboration, rather than purely head-to-head competition, reflects the complexity of addressing fibrotic disease biology and the value of complementary capabilities.

Actionable strategic initiatives that align translational biomarkers, supply chain resilience, regional regulatory engagement, and partnership models to accelerate successful therapeutic launches

Industry leaders should prioritize a set of actionable initiatives that align scientific promise with operational and commercial realities. First, integrate translational biomarker strategies early to de-risk clinical programs and create clear links between mechanism of action and clinical endpoints. This alignment will facilitate regulatory dialogue and strengthen value propositions for payers. Second, invest in supply chain resilience by diversifying suppliers for critical inputs, evaluating regional manufacturing options, and establishing contingency plans that preserve clinical and commercial continuity.

Third, pursue strategic collaborations that combine complementary capabilities: emerging innovators should seek partners for late-stage development and commercialization, while established companies can accelerate innovation through targeted licensing and co-development agreements. Fourth, tailor regional strategies to local regulatory and payer landscapes, engaging health technology assessment bodies and regional clinical networks to ensure evidence packages meet local requirements. Finally, design commercial models that reflect route of administration and distribution dynamics: ensure appropriate clinic-based support for injectable therapies and frictionless retail and online fulfillment for oral regimens.

By executing these recommendations, organizations can translate scientific advances into durable clinical impact while managing operational complexity and aligning stakeholder incentives across development and commercialization pathways.

A rigorous mixed-methods research approach combining expert primary interviews, systematic secondary literature review, and operational analysis to validate therapeutic and commercial insights

The research behind this report combines multiple methodological approaches to ensure a robust and evidence-based perspective. Primary research included structured interviews with clinical experts in hepatology, regulatory advisors, industry executives, and supply chain specialists to capture current practice patterns, regulatory expectations, and operational constraints. These qualitative insights were synthesized to contextualize therapeutic differentiation and to illuminate decision points that influence development and commercialization strategies.

Secondary research encompassed a systematic review of peer-reviewed literature, clinical trial registries, and publicly available regulatory guidance to map mechanistic rationales, clinical endpoints, and translational biomarkers. Operational analysis leveraged industry reports on manufacturing capabilities, supply chain frameworks, and distribution models to assess practical implications for development and market entry. Throughout the process, triangulation of evidence was applied to validate conclusions and to ensure that interpretations reflected multiple perspectives.

Analytical rigor was maintained through iterative validation with subject matter experts and cross-functional reviewers. The methodology prioritized clarity and reproducibility, with an emphasis on linking mechanistic science to clinical trial design and commercial execution. This approach supports decision-makers seeking actionable intelligence grounded in both scientific evidence and operational feasibility.

A conclusive synthesis highlighting actionable priorities across science, clinical development, operations, and commercial execution to realize durable therapeutic impact in liver fibrosis

In summary, the liver fibrosis therapeutic landscape is transitioning from conceptual promise to pragmatic execution. Scientific advances in target biology and modality engineering have expanded the set of viable interventions, while innovations in diagnostics and trial design are enabling more efficient proof-of-concept work. At the same time, operational pressures-ranging from supply chain shifts to tariff-related sourcing considerations-require integrated planning across R&D, manufacturing, and commercial teams.

Success in this environment will hinge on the ability to align mechanistic clarity with translational biomarkers, to design patient-centric clinical programs that reflect route of administration and distribution realities, and to engage payers and regulators early with robust evidence strategies. Strategic collaborations and adaptive operational models will be key enablers, allowing organizations to combine scientific differentiation with scale and market access expertise.

The outcome-oriented approach advocated throughout this report emphasizes measurable clinical benefit, durable patient outcomes, and pragmatic pathways to access. Stakeholders that adopt data-driven development, prioritize supply chain resilience, and pursue partnerships that complement internal capabilities will be best positioned to convert scientific innovation into sustained clinical and commercial success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emerging combination therapies targeting inflammation and fibrogenesis in liver fibrosis patients
  • 5.2. Advances in noninvasive imaging biomarkers accelerating early detection of liver fibrosis progression
  • 5.3. Stratified clinical trial designs leveraging genomic and metabolic biomarkers for patient selection in liver fibrosis drug development
  • 5.4. Regulatory momentum behind accelerated approval pathways for novel antifibrotic agents in hepatic disease management
  • 5.5. Strategic partnerships between biotech firms and academic centers driving discovery of next generation fibrogenesis inhibitors
  • 5.6. Rising adoption of oral small molecule therapies over injectables in chronic liver fibrosis treatment regimens
  • 5.7. Market access challenges influenced by high pricing strategies and evolving reimbursement policies for fibrosis drugs
  • 5.8. Integration of digital health solutions enabling remote monitoring of treatment response in liver fibrosis therapies
  • 5.9. Real world evidence from longitudinal disease registries shaping clinical guidelines and market penetration strategies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Liver Fibrosis Drugs Market, by Drug Class

  • 8.1. Biologic Therapies
    • 8.1.1. Monoclonal Antibodies
    • 8.1.2. Recombinant Proteins
  • 8.2. Cell Therapies
  • 8.3. Gene Therapies
  • 8.4. Small Molecule Inhibitors
    • 8.4.1. Natural Products
    • 8.4.2. Synthetic Compounds

9. Liver Fibrosis Drugs Market, by Mechanism Of Action

  • 9.1. ASK1 Inhibitors
  • 9.2. Galectin-3 Inhibitors
  • 9.3. PPAR Agonists
    • 9.3.1. PPAR Alpha
    • 9.3.2. PPAR Delta
    • 9.3.3. PPAR Gamma
  • 9.4. TGF Beta Blockers

10. Liver Fibrosis Drugs Market, by Route Of Administration

  • 10.1. Injectable
    • 10.1.1. Intravenous
    • 10.1.2. Subcutaneous
  • 10.2. Oral

11. Liver Fibrosis Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy
    • 11.3.1. Chain Pharmacy
    • 11.3.2. Independent Pharmacy

12. Liver Fibrosis Drugs Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Liver Fibrosis Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Liver Fibrosis Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Gilead Sciences, Inc.
    • 15.3.2. AbbVie Inc.
    • 15.3.3. F. Hoffmann-La Roche Ltd.
    • 15.3.4. Bristol-Myers Squibb Company
    • 15.3.5. Pfizer Inc.
    • 15.3.6. Novartis AG
    • 15.3.7. Takeda Pharmaceutical Company Limited
    • 15.3.8. Merck & Co., Inc.
    • 15.3.9. Intercept Pharmaceuticals, Inc.
    • 15.3.10. Madrigal Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. LIVER FIBROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. LIVER FIBROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. LIVER FIBROSIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CELL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CELL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CELL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CELL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CELL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CELL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GENE THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GENE THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GENE THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GENE THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GENE THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY NATURAL PRODUCTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY NATURAL PRODUCTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY NATURAL PRODUCTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY NATURAL PRODUCTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY NATURAL PRODUCTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY NATURAL PRODUCTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SYNTHETIC COMPOUNDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SYNTHETIC COMPOUNDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SYNTHETIC COMPOUNDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SYNTHETIC COMPOUNDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SYNTHETIC COMPOUNDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SYNTHETIC COMPOUNDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ASK1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ASK1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ASK1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ASK1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ASK1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ASK1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GALECTIN-3 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GALECTIN-3 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GALECTIN-3 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GALECTIN-3 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GALECTIN-3 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GALECTIN-3 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR ALPHA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR ALPHA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR ALPHA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR ALPHA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR ALPHA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR ALPHA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR DELTA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR DELTA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR DELTA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR DELTA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR DELTA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR DELTA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR GAMMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR GAMMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR GAMMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR GAMMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR GAMMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR GAMMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY TGF BETA BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY TGF BETA BLOCKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY TGF BETA BLOCKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY TGF BETA BLOCKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY TGF BETA BLOCKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY TGF BETA BLOCKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 286. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 293. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 294. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 297. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 298. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 299. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 300. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 301. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 302. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 303. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 304. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 305. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 306. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 307. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 308. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 313. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 314. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 315. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 316. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032